Literature DB >> 22223074

Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.

Shiro Miyayama1, Masashi Yamashiro, Yoshihiro Shibata, Masahiro Hashimoto, Miki Yoshida, Kazunobu Tsuji, Fumihito Toshima, Osamu Matsui.   

Abstract

PURPOSE: To compare local control effects of superselective transcatheter arterial chemoembolization (TACE) using epirubicin (EPI) plus mitomycin C (M) and miriplatin (MPT) for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: One-hundred and twenty-nine HCCs treated with superselective TACE were divided into three groups according to the type of anticancer drug; EPI-M-TACE (n = 51), MPT-TACE (n = 21), and MPT-I-TACE (MPT emulsion) (n = 57). Local recurrence, patterns of recurrence (intratumoral recurrence; IR), and follow-up angiograms were evaluated.
RESULTS: Mean tumor diameter and follow-up period for the EPI-M-TACE, MPT-TACE, and MPT-I-TACE groups were 16.9 mm and 15.5 months, 20.7 mm and 12.0 months, and 18.8 mm and 9.6 months, respectively. Local recurrence for the EPI-M-TACE, MPT-TACE, and MPT-I-TACE groups at 5, 10, and 15 months was 6.1, 47.6, and 40.1%, 23.5, 67.3, and 63.9%, and 26.2, 75.4, and 72.9%, respectively. IR for the EPI-M-TACE, MPT-TACE, and MPT-I-TACE groups was 23.1, 71.4, and 71.0%, respectively. Local recurrence and IR in the EPI-M-TACE group were significantly less than those in the MPT-TACE and MPT-I-TACE groups. Follow-up angiograms revealed less arterial damage in the MPT-TACE and MPT-I-TACE groups.
CONCLUSION: Superselective TACE using MPT resulted in very frequent local recurrence, in particular IR, despite less arterial damage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223074     DOI: 10.1007/s11604-011-0043-6

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  20 in total

1.  Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.

Authors:  K Kamada; T Nakanishi; M Kitamoto; H Aikata; Y Kawakami; K Ito; T Asahara; G Kajiyama
Journal:  J Vasc Interv Radiol       Date:  2001-07       Impact factor: 3.464

2.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

3.  [Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents].

Authors:  Kenji Ikeda; Takuji Okusaka; Masafumi Ikeda; Manabu Morimoto
Journal:  Gan To Kagaku Ryoho       Date:  2010-02

4.  Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Kei Sawara; Yasuhiro Miyamoto; Yukiho Kasai; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

5.  Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study.

Authors:  T de Baere; X Zhang; B Aubert; G Harry; C Lagrange; J Ropers; J Dufaux; J Lumbroso; P Rougier; M Ducreux; A Roche
Journal:  Radiology       Date:  1996-12       Impact factor: 11.105

6.  Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.

Authors:  Katerina Malagari; Mary Pomoni; Alexis Kelekis; Anastasia Pomoni; Spyros Dourakis; Themis Spyridopoulos; Hippokratis Moschouris; Emmanouil Emmanouil; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-24       Impact factor: 2.740

Review 7.  Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization.

Authors:  O Matsui; M Kadoya; J Yoshikawa; T Gabata; K Arai; H Demachi; S Miyayama; T Takashima; M Unoura; K Kogayashi
Journal:  Radiology       Date:  1993-07       Impact factor: 11.105

Review 8.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

9.  Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma.

Authors:  Takuji Okusaka; Shuichi Okada; Toshio Nakanishi; Shigetoshi Fujiyama; Yasuhiko Kubo
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.651

10.  Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.

Authors:  Mitsuharu Hanada; Akemi Baba; Yasuyuki Tsutsumishita; Toshihiro Noguchi; Takashi Yamaoka; Nobuyoshi Chiba; Fumio Nishikaku
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-24       Impact factor: 3.333

View more
  14 in total

Review 1.  Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Authors:  Norihiro Imai; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Yoshiki Hirooka; Hidemi Goto
Journal:  World J Hepatol       Date:  2014-12-27

2.  Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity.

Authors:  Takaaki Hasegawa; Haruyuki Takaki; Takashi Yamanaka; Masashi Fujimori; Atsuhiro Nakatsuka; Junji Uraki; Tomomi Yamada; Hajime Sakuma; Koichiro Yamakado
Journal:  Jpn J Radiol       Date:  2013-03-24       Impact factor: 2.374

3.  Preparation and evaluation of reduction-responsive nano-micelles for miriplatin delivery.

Authors:  Ying Zhang; Dejian Hu; Shangcong Han; Guowen Yan; Chao Ma; Chen Wei; Miao Yu; Dongmei Li; Yong Sun
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-06

4.  Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.

Authors:  Sota Oguro; Subaru Hashimoto; Tomoki Tanaka; Masanori Inoue; Seishi Nakatsuka; Sachio Kuribayashi; Keiko Asakura; Shigeyuki Kawachi; Minoru Tanabe; Yuko Kitagawa; Hirotoshi Ebinuma; Hidetsugu Saito; Toshifumi Hibi
Journal:  Jpn J Radiol       Date:  2012-08-28       Impact factor: 2.374

5.  Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma.

Authors:  Daisuke Yasui; Satoru Murata; Shiro Onozawa; Takahiko Mine; Tatsuo Ueda; Fumie Sugihara; Chiaki Kawamoto; Eiji Uchida; Shin-ichiro Kumita
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

6.  Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma.

Authors:  Toru Ishikawa; Satoshi Abe; Ryousuke Inoue; Tomoyuki Sugano; Yuhsuke Watanabe; Akito Iwanaga; Keiichi Seki; Terasu Honma; Takeo Nemoto; Keiko Takeda; Toshiaki Yoshida
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

7.  Cone-Beam Computed Tomography Correlates with Conventional Helical Computed Tomography in Evaluation of Lipiodol Accumulation in HCC after Chemoembolization.

Authors:  Toru Ishikawa; Satoshi Abe; Asami Hoshii; Yumi Yamada; Akihiko Iiduka; Takeo Nemoto; Keiko Takeda; Toshiaki Yoshida
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

8.  Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.

Authors:  Jin Iwazawa; Shoichi Ohue; Naoko Hashimoto; Takashi Mitani
Journal:  Cancer Manag Res       Date:  2012-04-19       Impact factor: 3.989

Review 9.  Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Tatsuo Ueda; Ken Nakazawa; Shiro Onozawa; Daisuke Yasui; Shin-ichiro Kumita
Journal:  ScientificWorldJournal       Date:  2013-03-27

10.  Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy.

Authors:  Naoko Hashimoto; Jin Iwazawa; Shoichi Ohue; Takashi Mitani
Journal:  Onco Targets Ther       Date:  2013-08-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.